Literature DB >> 16026485

The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders.

Vera A Morgan1, Philip B Mitchell, Assen V Jablensky.   

Abstract

OBJECTIVES: Data from the Australian National Study of Low Prevalence (Psychotic) Disorders were used to describe the clinical and sociodemographic profile of individuals with bipolar disorder, their levels of impairment and disability, and use of medication and treatment services.
METHODS: A 1-month census of contacts with mental health services, private psychiatric and general practices, as well as contact points in marginalized settings, was conducted in a national catchment of 1.1 million adults. The census yielded 3,800 individuals who screened positive for psychosis, of whom a random sample of 980 were administered a comprehensive semi-structured interview schedule. Results are presented on 112 persons with an ICD-10 diagnosis of bipolar disorder.
RESULTS: Overall, 69.6% of the 112 persons who met the ICD-10 criteria for bipolar disorder reported a recurrent episodic illness, 25.0% had a chronic course without clear remissions, and 5.4% had a single episode of mania. Assessed on a lifetime basis, suicidal ideation was common (78.6%) and levels of drug and alcohol abuse/dependence were high (32.1%). The majority (84.8%) had had at least one contact with inpatient, outpatient or emergency services in the previous year. Those with serious impairment had levels of service utilization similar to the rest of the sample, but were more likely to report a poorer quality of life and unmet service needs. While the percentage experiencing social and occupational dysfunction was substantial and similar for both sexes, women appeared to be better integrated socially than men. Comparisons with schizophrenia patients within the same survey sample highlighted less chronic impairment but equal or greater utilization of services by bipolar patients.
CONCLUSIONS: Despite low levels of chronicity, the burden of social disablement associated with bipolar disorder is high. The data suggest a number of important gaps in the provision of services for this predominantly treated population.

Entities:  

Mesh:

Year:  2005        PMID: 16026485     DOI: 10.1111/j.1399-5618.2005.00229.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  23 in total

1.  Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

Authors:  Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-03-01       Impact factor: 4.785

2.  Are there developmentally limited forms of bipolar disorder?

Authors:  David C Cicero; Amee J Epler; Kenneth J Sher
Journal:  J Abnorm Psychol       Date:  2009-08

Review 3.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

4.  Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.

Authors:  Kathleen R Merikangas; Robert Jin; Jian-Ping He; Ronald C Kessler; Sing Lee; Nancy A Sampson; Maria Carmen Viana; Laura Helena Andrade; Chiyi Hu; Elie G Karam; Maria Ladea; Maria Elena Medina-Mora; Yutaka Ono; Jose Posada-Villa; Rajesh Sagar; J Elisabeth Wells; Zahari Zarkov
Journal:  Arch Gen Psychiatry       Date:  2011-03

5.  Creatine Prevents Corticosterone-Induced Reduction in Hippocampal Proliferation and Differentiation: Possible Implication for Its Antidepressant Effect.

Authors:  Francis L Pazini; Mauricio P Cunha; Dayane Azevedo; Julia M Rosa; André Colla; Jade de Oliveira; Ana B Ramos-Hryb; Patricia S Brocardo; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

6.  What happens after diagnosis? Understanding the experiences of patients with newly-diagnosed bipolar disorder.

Authors:  Judith G Proudfoot; Gordon B Parker; Megan Benoit; Vijaya Manicavasagar; Meg Smith; Aimee Gayed
Journal:  Health Expect       Date:  2009-06       Impact factor: 3.377

7.  Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder.

Authors:  Berit Kerner; Anna J Jasinska; Joseph DeYoung; Maricel Almonte; Oi-Wa Choi; Nelson B Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-01-05       Impact factor: 3.568

8.  Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.

Authors:  Denis J David; Benjamin Adam Samuels; Quentin Rainer; Jing-Wen Wang; Douglas Marsteller; Indira Mendez; Michael Drew; Douglas A Craig; Bruno P Guiard; Jean-Philippe Guilloux; Roman P Artymyshyn; Alain M Gardier; Christophe Gerald; Irina A Antonijevic; E David Leonardo; René Hen
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

Review 9.  Burden of bipolar depression: impact of disorder and medications on quality of life.

Authors:  Erin E Michalak; Greg Murray; Allan H Young; Raymond W Lam
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Enhanced relapse prevention for bipolar disorder: a qualitative investigation of value perceived for service users and care coordinators.

Authors:  Eleanor Pontin; Sarah Peters; Fiona Lobban; Anne Rogers; Richard K Morriss
Journal:  Implement Sci       Date:  2009-02-09       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.